はじめての方へショーケース価格
  1. 米国企業
  2. Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc.DCPH

時価総額
$20.6億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日
Net loss--100-192-266-300-179-195
Stock-based compensation expense5102037465251
Depreciation expense0012332
Noncash lease expense---1-3-3-4-4
Acquired in-process research and development----4--
Gain on disposal of equipment-0--0---
Net amortization (accretion) of premiums (discounts) on marketable securities--42-217
Net amortization (accretion) of premiums (discounts) on marketable securities--42-217
Accounts receivable---14729
Inventory---31070
Prepaid expenses and other current assets16102810-4
Accounts payable3411-8158
Other long-term assets-----05
Accrued expenses and other current liabilities-4241427-164
Accounts payable3411-8158
Operating lease liabilities----1-3-3-3
Accrued expenses and other current liabilities-4241427-164
Income tax liabilities-----10
Operating lease liabilities----1-3-3-3
Accounts receivable---14729
Inventory---31070
Prepaid expenses and other current assets16102810-4
Accounts payable3411-8158
Other long-term assets-----05
Accrued expenses and other current liabilities-4241427-164
Accounts payable3411-8158
Operating lease liabilities----1-3-3-3
Accrued expenses and other current liabilities-4241427-164
Income tax liabilities-----10
Operating lease liabilities----1-3-3-3
Net cash flows used in operating activities--87-149-240-241-153-147
Purchases of marketable securities--8171,097335323323
Maturities of marketable securities---628469289335
Sales of marketable securities---50450-1
Purchases of property and equipment0155211
Proceeds from sale of equipment---0---
Acquired in-process research and development----4--
Acquired in-process research and development----4--
Increase in restricted investments-1020--
Increase in restricted investments-1020--
Net cash flows provided by (used in) investing activities--2-46128177-3413
Net cash flows provided by (used in) investing activities--2-46128177-3413
Proceeds from Issuance of Common Stock-1864322079164150
Payments of public offering costs4111001
Proceeds from Warrant Exercises-----00
Proceeds from Stock Options Exercised-1620623
Payments of public offering costs4111001
Net cash flows provided by financing activities-18643622715165152
Proceeds from Stock Options Exercised-1620623
Net cash flows provided by financing activities-18643622715165152
Net (decrease) increase in cash and cash equivalents---17316-49-22-
Net (decrease) increase in cash and cash equivalents------18
Effect of exchange rate changes on cash and cash equivalents------145,000910,000
Income tax liabilities-----10
Other long-term assets-----05
Proceeds from Warrant Exercises-----00